"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...

Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA ...

AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, through an exclusive licensing agreement that ...

AbbVie will be gaining rights to IGI Therapeutics’ lead candidate for oncology and autoimmune diseases in an exclusive ...

Discover 5 large cap stocks including Vodafone Idea and Paytm that surged up to 32% in one month - explore the top gainers ...

Gail Whiteford battled for four years to get the diagnosis with symptoms like back ache, excessive urinating, blood in her ...

A panelist highlights promising early-phase trial data on trispecific antibodies targeting multiple myeloma antigens and CD3, emphasizing their high response rates, manageable safety profiles, and ...

Panelists discuss how the CEPHEUS trial demonstrated that quadruplet therapy (daratumumab, bortezomib, lenalidomide, and dexamethasone) significantly improved minimal residual disease negativity rates ...

Coach Mike Shields, a Central Texas coaching veteran and Reicher alum, has died after battling cancer. He led with faith, ...

PDUFA date nears for GSK plc’s Blenrep (belantamab mafodotin), the U.S. FDA’s Oncologic Drugs Advisory Committee will decide July 17 on whether available data justify the return to market of the ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in ...

An expert discusses how adding an anti-CD38 antibody to a triplet backbone improved minimal residual disease (MRD) negativity and progression-free survival (PFS) in frail, transplant-ineligible ...